Therefore, it is critical to explore suitable biomarkers which accurately predict the prognosis of HCC patients receiving anti-PD-1/PD-L1 therapy, especially screen the advantage population for anti-PD-1/PD-L1 therapy before treatment, assist clinicians in making treatment decisions, and improve the prognosis of HCC patients. This evidence concerns the gene CD274 and hepatocellular carcinoma.